Hayden is an associate editor for The American Journal of Managed Care® (AJMC®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Multitask Learning Model Outperforms Traditional Machine Learning Models in RCTs, Developers Say
September 16th 2022The proposed multitask learning (MTL) model was developed using data from wearable devices worn by individuals in a randomized controlled trial (RCT) to predict outcomes of a depression treatment.
AHCL Insulin Delivery Linked to Better QOL, Metabolic Control in Children With T1D
September 15th 2022Children and adolescents with type 1 diabetes (T1D) saw improved quality of life (QOL) and metabolic control when using an advanced hybrid closed-loop (AHCL) insulin delivery method vs conventional therapy.
Digital Medication Monitor Linked to Better HRQOL, Lower Costs for Tuberculosis
September 15th 2022Patients with tuberculosis who used a digital medication reminder monitor had better health-related quality of life (HRQOL) and lower catastrophic costs compared with patients who used a standard therapy.
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
September 11th 2022While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
Subcutaneous Insulin Linked to Reduced Hospital Costs, LOS in Children With Mild DKA
September 10th 2022Treating children with mild diabetic ketoacidosis (DKA) using subcutaneous (SC) insulin aspart was linked to lower hospital costs and better efficacy of DKA management, compared with using intravenous (IV) insulin.
Dr David Koren on At-Risk Populations, Educational Efforts in Monkeypox
September 9th 2022David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, discussed the risk posed by monkeypox among immunocompromised individuals and men who have sex with men, as well as the need for educational efforts to address misconceptions tied to the disease.
Rifaximin Plus Lactulose Linked to Greater Effectiveness, Decreased Mortality in HE
September 9th 2022Compared with the use of lactulose alone, rifaximin plus lactulose can provide additional benefits in terms of increased effectiveness rate and decreased mortality in patients with hepatic encephalopathy (HE).
Survey Reveals Injectable HIV PrEP Preferences of Young Men Who Have Sex With Men
September 7th 2022Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and delivery method.
Gamified Therapy PDT Yields High Support From Children With Neurodevelopmental Disabilities
September 3rd 2022A digital pet app used as a prescription digital therapeutic (PDT) to encourage children to complete prescribed therapies received high engagement and function scores from children living with neurodevelopmental disabilities.
Dr David Koren Discusses Response to the Monkeypox Public Health Emergency
September 2nd 2022David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, speaks on gaps in monkeypox vaccine availability and access and steps to improve response to the public health emergency.
Gap After OCM May Cause Some Practices to Switch From Biosimilars to Brand Drugs
September 1st 2022The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Immune Responses to ART Vary by Regimen Among Individuals With Advanced HIV
August 30th 2022People with advanced HIV initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were more likely to reach CD4 cell count levels of 200 cells/mcL or higher compared with those initiating other antiretroviral therapy (ART) regimens.
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
August 29th 2022Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Black, Latinx Transgender Women Cite Multiple Motivations for PrEP Use
August 22nd 2022Black and Latinx transgender women expressed high levels of HIV risk perception at the individual and community level, both of which played major roles in their decision to start and continue pre-exposure prophylaxis (PrEP).